Skip to main content
. 2017 Jan 4;12:169–176. doi: 10.2147/COPD.S118596

Table 1.

Subject characteristics

Subject characteristics COPD Smokers Never-smokers P-value
Clinical characteristics
 Age, years 64±7.8 60±9.2 64±11.0 0.068A, 0.881B, 0.191C
 Male sex, % 53 40 30 0.339A, 0.083B, 0.520C
 Body mass index, kg/m2 24±3.6 26±3.4 25±3.1 0.074A, 0.406B, 0.379C
 Systolic blood pressure, mmHg 125±13 121±12 126±9.8 0.220A, 0.649B, 0.119C
 Diastolic blood pressure, mmHg 76±6.6 73±8.5 75±5.5 0.223A, 0.536B, 0.598C
 Heart rate, beats per minute 88±18 73±16 73±13 0.02A, <0.001B, 0.938C
 Smoking history, pack-years 65±37 39±23 0±0 0.04A, <0.001B, <0.001C
 Acute exacerbation rate, n/year 1.0 (0–1.6)
Lung function testing
 FVC, % predicted 78±17 104±13 103±16 <0.001A, <0.001B, 0.880C
 FEV1, % predicted 41±18 99±12 101±16 <0.001A, <0.001B, 0.655C
 FEV1/FVC ratio 43±15 82±8.2 84±10 <0.001A, <0.001B, 0.503C
Laboratory parameters
 LDL/HDL ratio 1.6±0.80 1.7±0.72 1.4±0.69 0.543A, 0.584B, 0.269C
 HbA1c, % 5.4±0.35 5.3±0.16 5.5±0.37 0.054A, 0.946B, 0.058C
 Creatinine, mg/dL 0.8±0.19 0.82±0.20 0.81±0.18 0.415A, 0.469B, 0.923C
 Neutrophils, ×103/mL 4.7±1.6 4.3±1.2 4.3±1.4 0.302A, 0.208B, 0.844C
 Interleukin-6, pg/mL 2.7 (1.6–5.3) 2.2 (1.5–3.4) 0.97 (0.74–1.8) 0.051A, <0.001B, 0.123C
Cardiovascular parameters
 B-IMT, mm 0.37±0.08 0.32±0.06 0.33±0.06 0.007A, 0.033B, 0.559C
 B-IMA, mm2 4.7±1.4 3.9±1.2 3.9±1.3 0.027A, 0.022B, 0.910C
 Pro-BNP, pg/mL 82 (47–161) 74 (45–166) 76 (36–177) 0.975A, 0.771B, 0.814C
 ADMA, μmol/L 0.47 (0.42–0.54) 0.55 (0.52–0.62) 0.54 (0.43–0.59) 0.131A, 0.817B, 0.135C

Notes: P-values are not significant unless presented.

A

COPD versus smokers;

B

COPD versus nonsmokers;

C

nonsmokers versus smokers.

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin; B-IMT, brachial intima-media thickness; B-IMA, brachial intima-media area; Pro-BNP, pro b-type natriuretic peptide; ADMA, asymmetric dimethylarginine.